Earnings recap and context

Caribou Biosciences (CRBU) has just posted another quarterly loss, with Q3 FY 2025 revenue of about US$2.2 million and basic EPS of US$0.30 in the red, underscoring that the company is still firmly in investment mode. Over recent periods, revenue has moved in a tight band between roughly US$2.0 million and US$3.5 million per quarter, while quarterly basic EPS has ranged from a loss of US$0.30 to US$0.58. This gives investors a clear view of a business that is still pre profit with early clinical programs. With margins under pressure and losses sizeable, the key question now is whether the pipeline and future revenue potential justify the current level of ongoing spend.

With the latest numbers on the table, the next step is to set these results against the widely held narratives around revenue growth potential, persistent losses, and valuation to see which views hold up and which might need a rethink.

TTM revenue near US$9.3 million against heavy losses

• On a trailing 12 month basis, Caribou generated about US$9.3 million of revenue while recording a net loss of roughly US$157.1 million, which shows revenue is still very small compared with the size of the loss.
• Supporters often focus on the potential of early programs, but the data here underline how early stage the business still is:
  • Across the last six reported quarters, revenue has sat in a narrow band of roughly US$2.0 million to US$3.5 million per quarter, while quarterly net losses have ranged between about US$27.5 million and US$54.1 million.
  • All lead assets in the AI generated narrative sit in Phase 1, which fits with these numbers showing modest revenue alongside sizeable, recurring losses.

Losses rising over time remain the central risk

• Over the past five years, losses have grown at about 25.8% per year on average and models in the supplied data expect earnings to decline by around 9% per year over the next three years, so the company is expected to stay unprofitable based on those figures.
• Critics point to this pattern as a key concern and the recent numbers line up with that caution:
  • In the last six quarters provided, net losses have ranged from about US$27.5 million up to US$54.1 million per quarter, and trailing 12 month losses sit around US$157.1 million.
  • With EPS on a trailing 12 month basis at roughly a US$1.70 loss per share, the earnings trend in the data is consistent with the view that profitability is some way off.

P/S of 18.3x prices in strong revenue forecasts

• The shares trade on a P/S of 18.3x compared with about 11.4x for the wider US biotechs group and roughly 3x for peers, while the current share price is US$1.82, meaning investors are paying a higher multiple of sales than the averages given.
• Supporters might argue the premium is linked to strong revenue growth forecasts, but the figures also leave little room for disappointment:
  • Revenue is forecast in the supplied data to grow around 63.3% per year against a 10.3% forecast for the broader US market, which helps explain why the stock trades above the sector and peer P/S levels.
  • At the same time, those same models expect earnings to fall by about 9% per year and do not show a move into profitability over the next three years, so the higher P/S multiple is currently backed by revenue expectations rather than improving earnings in this dataset.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Caribou Biosciences's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If this mix of risks and potential rewards leaves you on the fence, this may be a good time to review the full picture for yourself using 1 key reward and 2 important warning signs.

See What Else Is Out There

Caribou Biosciences is still posting sizeable losses against modest revenue with all key programs in early Phase 1, so profitability and cash self sufficiency appear distant.

If that level of ongoing loss makes you want a steadier profile, check out our 63 resilient stocks with low risk scores to quickly spot companies where risk scores look more controlled.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.